Savient Pharma rises high (NASDAQ:SVNT)
Source: http://www.favstocks.com/savient-pharma-rises-high-nasdaqsvnt/121207/Posted on Monday, October 12th, 2009 | In Biotech, Investing Lessons, Stocks to Watch
On a late Friday afternoon, shares of Savient Pharmaceuticals bounced back as analysts for Oppenheimer and Co. raised his views on Savient Pharmaceuticals and its new chronic gout drug candidate Krystexxa. The analysts have stated that he is optimistic that Savient Pharmaceuticals will be able to resolve the manufacturing issues related with the commercial use of Krystexxa. Currently, Savient Pharmaceuticals have Oxandrin as their only commercially successful drug in the United States market which is a synthetic testosterone derivative that helps to promote weight gain after weight loss following extensive surgery, chronic infections and severe trauma.
However, Savient Pharmaceuticals’ new drug Krystexxa is a biologic drug that is used for the treatment of those patients who are unable to take conventional gout treatments, or for those who are not responding to traditional gout treatments. Technically, Krystexxa is a PEGylated recombinant mammalian urate oxidase. It works by breaking down the uric acid, a substance that causes gout in human body. Krystexxa is administered intravenously every two weeks and helps in the reduction of gout tophi, tender or swollen joints, and reduction of flashes as well. However, there are adverse side-effects to Krystexxa that cannot be overlooked and it is still under the review by the Food and Drug Administration panel on the risk-versus-benefit basis.
In August 2009, Savient Pharmaceuticals had announced that they have received a complete response letter from the FDA stating that they cannot approve Krystexxa at the moment considering the side-effects it has. Also, the FDA stated concerns over the manufacturing process for the commercial use of Krystexxa. Savient Pharmaceuticals will work with FDA and resubmit their reports perhaps in early 2010.
Shares of Savient Pharmaceuticals went up 7.4 percent in the afternoon trading soon after the stocks were upgraded by the analysts.
FavStocks.com – Source
Copyright © 2009 FavStocks.com – Written by Sandra Kitchen
Please visit FavStocks.com for more info on your Favorite Stocks. Also stop by the free Stock Market Forum and discuss todays hot stocks.
This feed is for personal, non-commercial use only unless specifically authorized. (Digital Fingerprint:
dd2e38dc00df25f652aea569904b31ab (67.225.178.66) )
Last 5 posts by Sandra Kitchen
- Novo Nordisk races ahead (NYSE:NVO) - October 26th, 2009
- Microsoft Sales Slip (NASDAQ:MSFT) - October 23rd, 2009
- Lupus Drug Data Fuels HGS (NASDAQ:HGSI) - October 21st, 2009
- AstraZeneca’s Crestor Approved (NYSE:AZN) - October 19th, 2009
- Progenics-Wyeth Agreement (NASDAQ:PGNX) - October 16th, 2009
 About Sandra Kitchen (http://www.favstocks.com)
Sandra has been avidly involved in watching the stock market and writing about the stock movements that interest investors. She specializes in small and mid-cap Biotech stocks with a main focus on public companies awaiting FDA approval of new drugs and/or products. Living in New York, with her family and pets, she stays up on the latest news from the New York Stock Exchange and the FDA. Her goal is to bring the news to investors from a fresh, unbiased, pure research point of view. |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.